Pfizer Inc. (NYSE:PFE) has issued its financial guidance for the full year 2025, projecting revenue growth between $61 billion and $64 billion, representing a flat 5% operational increase from the midpoint of its 2024 guidance. The pharmaceutical giant also forecast adjusted diluted earnings per share (EPS) to rise between 10% and 18%, ranging from $2.80 to $3.00 per share, aligning closely with Wall Street expectations.
The company’s outlook factors in a $1 billion unfavorable impact from changes to Medicare Part D under the Inflation Reduction Act. Despite this, Pfizer stated it will continue implementing cost realignment strategies and manufacturing optimizations to achieve financial stability amid evolving market conditions.
Pfizer’s projections come at a pivotal moment for the company, which has faced sharp declines in revenue following the pandemic-driven peak of its COVID-19 vaccine and treatment sales. The company expects 2025 sales for its COVID-19-related products to remain consistent with 2024 levels. Shares of Pfizer, which have dropped nearly 12% year-to-date, saw a modest rise of 2% in premarket trading following the guidance announcement.
To strengthen its long-term growth prospects, Pfizer is focusing on advancing its drug pipeline, particularly in areas such as oncology and weight management. The company is currently conducting Phase 2 trials for danuglipron, an oral GLP-1 receptor agonist targeting weight loss. Early results have shown promise in reducing body weight, but the drug faces significant competition from established GLP-1 treatments such as Ozempic and Wegovy, which have gained widespread adoption.
Pfizer’s leadership, under CEO Albert Bourla, has faced increasing scrutiny from investors, including activist hedge fund Starboard Value, which criticized the company’s acquisition strategy and its return on research and development investments. In response, Pfizer has prioritized cost management, debt reduction, and portfolio streamlining to rebuild investor confidence.
Analysts remain cautiously optimistic about Pfizer’s pipeline, with JP Morgan analyst Chris Schott noting that while certain assets, particularly in oncology, appear promising, more significant progress will likely emerge beyond 2026. The near-term forecast reflects stability but highlights ongoing challenges in driving substantial revenue growth.
As part of its Medicare-related adjustments, Pfizer acknowledged the additional financial pressures introduced by manufacturer discounts under the new legislation. The company anticipates these changes will offset expected benefits from the upcoming $2,000 cap on out-of-pocket expenses for seniors enrolled in Medicare Part D.
Pfizer plans to provide further details on its financial outlook and strategic priorities during a scheduled conference call with analysts later today. Investors and stakeholders will closely monitor the company’s progress in navigating post-pandemic headwinds while advancing its pipeline to meet future growth expectations. – By EuroWire News Desk.
